Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

Clinical trial NCT02952729 · COMPLETED

Trial details

NCT number: NCT02952729
Sponsor: Mersana Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Breast Cancer Advanced Nonsmall Cell Lung Cancer Advanced Gastric Cancer

Start date: 2016-11-21
Primary completion: 2019-01-28
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.